UNITY Biotechnology (UBX) Stock Price, News & Analysis

Company Overview

UNITY Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on the development of senolytic therapies designed to selectively eliminate senescent cells that contribute to a range of age-related diseases. Headquartered in South San Francisco, California, UNITY leverages cutting-edge cellular and molecular biology platforms to identify and prioritize targets involved in cellular senescence. The company’s proprietary R&D engine integrates transcriptomic, proteomic, and high-throughput screening data to advance programs through lead optimization and preclinical validation.

UNITY’s most advanced program, UBX1325, is a small-molecule inhibitor targeting the Bcl-xL protein and is being evaluated in clinical trials for the treatment of diabetic macular edema and other retinal diseases. Another pipeline asset, UBX0101, was investigated for osteoarthritis and served as an important proof of concept for the therapeutic potential of senolytics in degenerative joint disorders. The company’s portfolio further includes earlier-stage candidates aimed at idiopathic pulmonary fibrosis and other fibrotic conditions, reflecting a commitment to addressing indications driven by chronic inflammation and tissue remodeling.

Founded in 2011 by Dr. Nathaniel David and Antonio Olivas, UNITY Biotechnology has assembled a leadership team with deep expertise in drug discovery and development. Dr. David, a veteran of Genentech’s oncology research division, serves as Executive Chairman, while the senior management team includes veterans from leading pharmaceutical and biotech organizations. This blend of scientific rigor and strategic business acumen has enabled UNITY to forge collaborations, including an R&D partnership with Roche aimed at exploring senescence biology in oncology settings.

With research operations in both the United States and Europe, UNITY Biotechnology remains at the forefront of translational aging research. The company’s approach seeks not only to alleviate symptoms but to modify the underlying drivers of age-related pathologies, positioning its pipeline for potential applications across a broad spectrum of diseases with high unmet medical need.

Key Stats

• Today's Range: $0.20 to $0.32
• 50-Day Range: $0.18 to $1.12
• 52-Week Range: $0.20 to $3.10
• Volume: 3.73 million shs
• Average Volume: 275,416 shs
• Market Capitalization: $3.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.75
• Consensus Rating: Moderate Buy

UNITY Biotechnology Stock Analysis - MarketRank™

UNITY Biotechnology scored higher than 84% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

UNITY Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

UNITY Biotechnology has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for UNITY Biotechnology are expected to grow in the coming year, from ($1.45) to ($1.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of UNITY Biotechnology is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of UNITY Biotechnology is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

UNITY Biotechnology has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.65% of the float of UNITY Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

UNITY Biotechnology has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in UNITY Biotechnology has recently decreased by 34.44%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

UNITY Biotechnology does not currently pay a dividend.

Dividend Growth

UNITY Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.60

Percentage of Shares Shorted

3.65% of the float of UNITY Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

UNITY Biotechnology has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in UNITY Biotechnology has recently decreased by 34.44%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for UNITY Biotechnology this week, compared to 0 articles on an average week.

Search Interest

Only 5 people have searched for UBX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

MarketBeat Follows

1 people have added UNITY Biotechnology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, UNITY Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.80% of the stock of UNITY Biotechnology is held by insiders.

Percentage Held by Institutions

Only 29.49% of the stock of UNITY Biotechnology is held by institutions.

UBX Stock Analysis - Frequently Asked Questions

How have UBX shares performed this year?

UNITY Biotechnology's stock was trading at $0.9764 on January 1st, 2025. Since then, UBX stock has decreased by 81.7% and is now trading at $0.1790.

How were UNITY Biotechnology's earnings last quarter?

UNITY Biotechnology, Inc. (NASDAQ:UBX) issued its quarterly earnings data on Tuesday, April, 22nd. The company reported ($0.43) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.43).

When did UNITY Biotechnology's stock split?

Shares of UNITY Biotechnology reverse split on Thursday, October 20th 2022.The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did UNITY Biotechnology IPO?

UNITY Biotechnology (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

How do I buy shares of UNITY Biotechnology?

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of UNITY Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that UNITY Biotechnology investors own include Plug Power (PLUG), NVIDIA (NVDA), NIO (NIO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Enovix (ENVX) and Nokia (NOK).

Company Calendar

• Last Earnings: 4/22/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 7/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:UBX
• CIK: 1463361
• Web: www.unitybiotechnology.com
• Phone: (650) 416-1192
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for UNITY Biotechnology: $3.75
• High Price Target: $8.00
• Low Price Target: $1.00
• Potential Upside/Downside: +1,995.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.99 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -246.82%
• Return on Assets: -58.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.95
• Quick Ratio: 1.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.39 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 17,212,000
• Free Float: 16,214,000
• Market Cap: $3.08 million
• Optionable: Optionable
• Beta: 0.92